Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)
Cost: FreeView Offer chevron_right
Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding.
After completing Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:
- Describe the limitations of annual bleed rate as an epidemiological measure in Hemophilia A
- Define early prophylaxis in severe hemophilia A and describe its impact on osteochondral damage
- List evidence-supported benefits of extending clotting factor half lives
- Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia A, and apply them to patient cases
- Describe the emerging therapies in the treatment of hemophilia A
hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with Hemophilia A.